Related Experiment Video
Updated: Jul 14, 2025
Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
Published on: July 26, 2022
The therapeutic effects of mesenchymal stem cell (MSCs) exosomes in covid-19 disease; Focusing on dexamethasone
Ehsan Derafsh1, Farnoosh Ebrahimzadeh2, Mohammad Saeed Kahrizi3
1Department of Basic Medical Science, Windsor University School of Medicine, Brighton's Estate, Cayton, Saint Kitts and Nevis.
Abstract:
The study of diseases, specifically their aetiologies, their step-by-step progressions (pathogenesis), and their impact on normal structure and function, is the focus of pathology, a branch of science and medicine. In therapeutic fields, it is critical to decrease significantly elevated levels of proinflammatory cytokines. The immunomodulatory drugs such as dexamethasone have been used in several of inflammatory diseases such as Covid-19. The use of dexamethasone alone or in combination with other drugs or method such as mesenchymal stem cell (MSC) is one of the most up-to-date discussions about Covid-19. In this review, we first examined the effects of dexamethasone as monotherapy on inflammatory cytokines and then examined studies that used combination therapy of dexamethasone and other drugs such as Baricitinib, Tofacitinib and tocilizumab. Also, therapeutic aspects of MSCs are examined in this review.
Insights
Dexamethasone effectively reduces inflammatory cytokines in COVID-19. Combination therapies, including dexamethasone with other drugs or mesenchymal stem cells (MSCs), are also explored for managing inflammatory diseases.
Area of Science:
- Pathology and immunology, focusing on disease mechanisms and therapeutic interventions.
Background:
- Elevated proinflammatory cytokines are critical targets in treating inflammatory diseases like COVID-19.
- Immunomodulatory drugs, such as dexamethasone, are utilized in managing inflammatory conditions.
Purpose of the Study:
- To review the efficacy of dexamethasone monotherapy in modulating inflammatory cytokines.
- To examine combination therapies involving dexamethasone with other agents or mesenchymal stem cells (MSCs) for COVID-19 treatment.
Main Methods:
- Literature review of studies on dexamethasone's effects on inflammatory cytokines.
- Analysis of combination therapies including dexamethasone with Baricitinib, Tofacitinib, and tocilizumab.
- Examination of the therapeutic potential of mesenchymal stem cells (MSCs).
Main Results:
- Dexamethasone monotherapy demonstrates effects on inflammatory cytokine levels.
- Combination therapies show promise in managing cytokine storms associated with COVID-19.
- Mesenchymal stem cells (MSCs) present potential therapeutic applications in inflammatory diseases.
Conclusions:
- Dexamethasone is a key therapeutic agent for controlling inflammation in COVID-19.
- Combined therapeutic strategies involving dexamethasone and MSCs warrant further investigation for enhanced immunomodulation.
More Related Videos
07:03Isolation, Characterization, and Therapeutic Application of Extracellular Vesicles from Cultured Human Mesenchymal Stem Cells
Published on: September 23, 2022
08:13Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
Published on: April 10, 2019
Related Concept Videos
01:19Mesenchymal Stem Cells
01:36Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...